0001415889-22-005831.txt : 20220527 0001415889-22-005831.hdr.sgml : 20220527 20220527170128 ACCESSION NUMBER: 0001415889-22-005831 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220526 FILED AS OF DATE: 20220527 DATE AS OF CHANGE: 20220527 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shaff Eric D. CENTRAL INDEX KEY: 0001643734 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39746 FILM NUMBER: 22978705 MAIL ADDRESS: STREET 1: C/O SERES HEALTH, INC. STREET 2: 161 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc. CENTRAL INDEX KEY: 0001821323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474005543 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-336-7540 MAIL ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 form4-05272022_050545.xml X0306 4 2022-05-26 0001821323 Sigilon Therapeutics, Inc. SGTX 0001643734 Shaff Eric D. C/O SIGILON THERAPEUTICS, INC. 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 true false false false Stock Option (Right to Buy) 0.7632 2022-05-26 4 A 0 8888 0 A 2032-05-25 Common Stock 8888 8888 D The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023. /s/ Matthew Kowalsky, Attorney-in-Fact 2022-05-27